Company CEREP Euronext Paris
Equities
FR0004042232
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
2023 | Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2022 | Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022 | CI |
Business Summary
Exports account for 97.9% of net sales.
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Preclinical Drug Research Services
100.0
%
| 42 | 100.0 % | 48 | 100.0 % | +14.45% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
International
97.7
%
| 38 | 90.9 % | 47 | 97.7 % | +23.05% |
France
2.3
%
| 4 | 9.1 % | 1 | 2.3 % | -71.19% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 18/04/18 | |
Damien Séroux
CHM | Chairman | - | 12/10/14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Damien Séroux
CHM | Chairman | - | 12/10/14 |
Director/Board Member | 68 | 09/06/15 | |
Chief Executive Officer | - | 18/04/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,044 | 213 ( 4.223 %) | 0 | 4.223 % |
Company contact information
Eurofins-Cerep SA
Le bois l'Evêque
86600, Celle l'Evescault
+33 5 49 89 30 00
http://www.eurofins.fr/cerep/Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALECR Stock
- Stock
- Company CEREP